FRA
BHVN

Front Row Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Front Row Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49
Closed -$7K – 950
2022
Q2 		$7K Buy
49
+18
+58% +$2.3K ﹤0.01% 604
2022
Q1 		$4K Hold
31
– – ﹤0.01% 781
2021
Q4 		$4K Buy
+31
New +$3.94K ﹤0.01% 808

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Front Row Advisors's BHVN Position: Q3 2022 in Review

Front Row Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 49 shares — an estimated $7K sold.

Front Row Advisors first reported a position in BHVN in Q4 2021 and held it in 3 quarters. The position peaked at $7K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Front Row Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Front Row Advisors sold 49 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $7K.
  • Front Row Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 3 quarters.
  • Front Row Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7K in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Front Row Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.